|Report : Traffic light status report 08/03/2021 02:43:38|
|The Mid Yorkshire Hospitals|
Traffic Light Status Information
|Responsibility for prescribing may be transfered from secondary care/specialist services to primary care with the agreement of an individual GP, and when locally approved and agreed shared care arrangements have been established (e.g. approved shared care guideliines are available).
Drugs that do not have written shared care guidelines may be prescribed in primary care at the GP's discretion. The GP should be satisfied that he/she has all the information and support needed to prescribe and monitor the patient.
Medicines with the following criteria should be classified as Amber: Drugs that require specialist/consultant assessment to enable patient selection and initiation of treatment, plus one or more of the following:
1. Require short or medium term specialist monitoring of efficacy.
2. Require short or medium term specialist monitoring of toxicity.
3. Are very rarely used, such that individual GPs are unlikely to see sufficient patients and acquire a working knowledge of the drug.
|Drugs that have been classified as "black" are those drugs that commissioning organisations across the South West Yorkshire Area Prescribing Committee boundaries have agreed with local trusts and clinicians that they will not commission locally. Medicines with the following crieteria should be classified as black:
1. There us a clear NHS England specialised commissioning group decision to not routinely fund usage of the drug.
2. There is a NICE recommendation that the drug should not be prescribed on the NHS for the condition specified.
3. A medicine for which the Areas Prescribing Committee considers there is a poor evidence base or lack of cost effectiveness compared to alternative commissioned treatments.
4. There is a CCG local decision not to routinely fund.
|Drugs that are appropriate for initiation and ongoing prescribing in primary or secondary care.
|These drugs are not recommended for use in normal practice.
Medicines are included on the basis of safety, efficacy and cost-effectiveness. The list is intended to support good prescribing and help make balanced decisions.
The medicines that are included in the grey list do not mean a complete ban on the use of these medicines. Inclusion should instead encourage the prescriber to think carefully before prescribing or recommending these medicines. These should only be prescribed in exceptional circumstances and practices are requested to review prescribing practice in order to ensure prescriptions of these drugs are reduced.
|Prescribing responsibility should remain with the consultant or specialist clinician.
Medicines with one or more of the following criteria should be categorised as Red.
These are drugs that:
1. Are unlicensed medicines unsuitable for use in primary care or are being used "off-label" for an indication with no established evidence base.
2. Require long-term on-going specialist monitoring of efficacy or require long-term on-going specialist monitoring of toxicity (either because of difficulty in recognising side effects or high cost/availability of investigations to identify toxicity).
3. Are specifically designated as hospital only by product licence or MHRA.
4. Are being used as part of a hospital based clinical trial.
5. Are not listed in the current BNF or BNFC.
6. Are part of a defined commissioning arrangement.